ABBV AbbVie
- Official Name: ABBVIE INC.
- Headquarters: 1 N Waukegan Rd, NORTH CHICAGO, IL, 60064 US
- CEO: Robert A. Michael
- Website: abbvie.com
- Key Investor: VANGUARD GROUP INC | 9.85%
- Dedicated Investor: LIVELSBERGER FINANCIAL ADVISORY | 41.31%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-18 | 1 | Lost by 2.207 | (0.476) - 1.731 | ||
| 2025-07-25 | 2 | Lost by 2.940 | 0.566 - 3.506 | ||
| 2025-07-29 | 2R | Won by 0.614 | 2.272 - 1.658 | ||
| 2025-08-01 | 3 | Won by 11.730 | 2.032 - (9.698) | ||
| 2025-08-07 | 1R | Won by 0.838 | 1.321 - 0.483 | ||
| 2025-08-08 | 4 | Won by 2.815 | 4.828 - 2.013 | ||
| 2025-08-12 | 3R | Lost by 1.996 | (0.913) - 1.083 | ||
| 2025-08-15 | 5 | Won by 4.691 TOTW | 5.345 - 0.654 | ||
| 2025-08-20 | 1R | Won by 2.500 | 1.521 - (0.979) | ||
| 2025-08-21 | 2R | Lost by 2.166 | 0.257 - 2.423 | ||
| 2025-08-22 | 6 | Won by 1.330 | 1.715 - 0.385 | ||
| 2025-08-29 | 7 | Lost by 2.417 | (0.062) - 2.355 | ||
| 2025-09-03 | 2R | Won by 1.017 | (0.028) - (1.045) | ||
| 2025-09-05 | 8 | Lost by 0.428 | 0.975 - 1.403 | ||
| 2025-09-12 | 9 | Won by 3.532 | 2.886 - (0.646) | ||
| 2025-09-17 | 3R | Won by 4.204 | 2.133 - (2.071) | ||
| 2025-09-19 | 10 | Won by 0.067 | 1.810 - 1.743 | ||
| 2025-09-26 | 11 | Lost by 2.221 | (0.730) - 1.491 | ||
| 2025-10-01 | QF | Lost by 3.537 | 5.264 - 8.801 | ||
| 2025-10-03 | 12 | Won by 3.314 | 5.178 - 1.864 | ||
| 2025-10-10 | 13 | Lost by 0.085 | (1.328) - (1.243) | ||
| 2025-10-17 | 14 | Lost by 2.122 | (0.438) - 1.684 | ||
| 2025-10-24 | 15 | Lost by 2.163 | (0.664) - 1.499 |
Latest News
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.
How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap
Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio s...
What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?
AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in A...
Best Dividend Kings: September 2026
Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
InMode (INMD) stays rangebound as US sales slip; global growth and consumables stabilize. Read here for a detailed investment analysis.
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ...
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations...
U.S. FDA Approves Juvmo (Tavapadon) For Parkinson’s Disease In Adults On Sept 25, 2026
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with s...
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually recei...
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balanc...
ADARx Pharmaceuticals raises $446 million in upsized IPO
The San Diego RNA drug developer sold 26.3 million shares at $17 apiece, with AbbVie investing up to $100 million in a concurrent private placement
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
RNAi drug specialist ADARx raises $446M IPO
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparv...
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells ...
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuation...
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
Iambic widens the discovery search, but AbbVie disclosed no targets, payment amounts or development timetable.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's wide...
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie (NYSE: ABBV) announced today that Health Canada has issued a Notice of Compliance for EPKINLY® (epcoritamab) with a new follicular lymphoma (F...
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
It would be hard for investors to replicate the company's return over the past decade.
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 a...
AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'
AbbVie is rated a "Sell" with a $191 target, implying 27.7% downside from the current $264 price. Click here to read more about the ABBV sto...
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned th...
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy t...
Recent Filing Shows That Rep. Pete Sessions Sold Over $100K Worth of Apple Stock
A September filing shows that Representative Pete Sessions reported a sale in Apple (NASDAQ:AAPL), valued between $100,001 and $250,000. The transacti...
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the ...
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Aller...
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticula...
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activ...
Congressman with $11.5 Million in Trades Keeps Selling Stocks: Here’s the Latest Moves
A member of Congress continues to sell stocks, with no buys since 2024. Here are the latest names traded.
SBIO: Big Pharma Needs What This Fund Owns
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of ...
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Joh...
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) a...
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growt...
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the global industry leader in aesthetics, today announced the U.S. launch of AA Signature™. Bui...
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization